Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019

GAITHERSBURG, Md., April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, May 2, 2019.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com, and connect with us on Twitter and LinkedIn.

Contacts:      

InvestorsErika TrahanSenior Manager, Investor & Public Relations[email protected]240-268-2000

Westwicke PartnersJohn Woolford[email protected]443-213-0506

MediaSam BrownAndrea Cohen[email protected]917-209-7163

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• EQT Corp. (EQT) Tops Q1 EPS by 17c; offers outlook
• West Fraser Timber Co. Ltd. (WFG) Tops Q1 EPS by 17c